Top News in R&D
 
 

 

 

READ ONLINE

 

 
 
 
 Global Health Technologies Coalition 
 
 
 
 

 

R&D News Roundup: May 30, 2023

 

Top News in R&D

Diagnostics get global recognition
The Lancet (5/27)

At the 76th World Health Assembly last week, World Health Organization (WHO) member states adopted a resolution on strengthening diagnostics capacity, following a recommendation from the Executive Board earlier this year. The resolution is aimed at raising global awareness of the importance of diagnostics and the major gaps in access, to even the most basic diagnostics, that are faced around the world. Implementation of the resolution will be driven by national governments, which are urged in the resolution to integrate national diagnostics strategies that address the regulation, assessment, and management of diagnostics into their national health plans, as well as to develop a national essential diagnostics list, which will hopefully lead to wider availability and access.

‘A gamechanger’: new meningitis vaccine hailed as major step
The Guardian (5/25), features PATH

An affordable meningitis vaccine designed to protect against multiple strains was found to be effective in phase 3 trials in Mali and the Gambia. The NmCV-5 vaccine, developed by PATH and the Serum Institute of India, generated a strong immune response against the five primary meningococcal strains in Africa, including the emerging X strain, for which there is currently no licensed vaccines. The cost of available vaccines for the four other strains of meningitis are currently too high for most African countries to buy the tens of millions of doses they need. NmCV-5 is expected to be available in the coming months and has the potential to dramatically reduce vaccine-preventable cases and deaths, especially those linked to the X strain.

Using AI, scientists find a drug that could combat drug-resistant infections
MIT News (5/25)

Using artificial intelligence, researchers at the Massachusetts Institute of Technology and McMaster University have identified a new antibiotic drug to combat Acinetobacter baumannii, which is responsible for many drug-resistant infections and can lead to pneumonia and meningitis. The drug was identified using a machine-learning model that was trained to evaluate whether drug compounds would inhibit A. baumanii’s growth, which then reviewed a library of nearly 7,000 potential compounds. The finding has the potential to reduce drug-resistant infections and also highlights the potential role of artificial intelligence in accelerating the search for novel antibiotics in the face of growing antimicrobial resistance.

 

 

News from GHTC

Virtually ouch-free: Promising early data on a measles vaccine delivered via sticker
NPR (5/26), features the Bill & Melinda Gates Foundation

Novel HIV vaccine candidate stimulates immune response in T cells
IAVI feature (5/25)

HERA donates $8.6 million for fight against antimicrobial resistance
CIDRAP (5/22), features the Global Antibiotic Research & Development Partnership (GARDP)

UK to provide up to £39m for AMR research
Pharmaceutical Technology (5/22), features the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
Related press release from the UK Government (5/22)

UK Government invests £5 million in GARDP to boost antibiotic development and access
GARDP press release (5/22)

Groundbreaking clinical trial to improve treatment for newborns with life-threatening sepsis gets underway in South Africa and Kenya
GARDP press release (5/22)

Community and civil society demand their voices be heard in UN political declaration on TB
Health Policy Watch (5/19), cowritten by Treatment Action Group and IAVI

Government of Canada makes important investment to fight antimicrobial resistance (AMR)
Government of Canada news release (5/11), features CARB-X

Stark-Watzinger: We urgently need new approaches for the prevention, diagnosis and treatment of superbugs
Federal Ministry of Education and Research press release (5/10), features CARB-X

 

 

Highlights From the Week

 

 

COVID-19 R&D Roundup

 

 

Upcoming Events